Oncotelic Therapeutics (OTCQB: OTLC) and its 45%-owned subsidiary, Sapu Nano (US) LLC, reported that the independent Safety Review Committee has completed its review of the initial three-patient safety cohort in the ongoing Phase 1b SP-03-B101 trial of Sapu003. The committee found no dose-limiting toxicities and recommended advancement to the next planned dose level. The company also announced plans to expand the study into Europe with additional clinical sites to broaden patient access and support enrollment.
The clinical milestone follows the publication of peer-reviewed research describing the scientific foundation of the Deciparticle(TM) nanomedicine platform and the intravenous everolimus formulation Sapu003. The company said the publication supports the platform's scalable manufacturing capabilities, stability and preclinical antitumor activity while reinforcing the ongoing clinical development program. The full press release is available at https://ibn.fm/sBbID.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic also licenses and co-develops drug candidates through joint ventures, including a 45% stake in GMP Bio, which advances its own pipeline of drug candidates complementing Oncotelic's strategic position in oncology and rare disease therapeutics.
The company also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through Oncotelic's relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the platform and its ongoing joint development work with TechForce Robotics, Oncotelic's strategic robotics and automation partner. For more information, visit www.oncotelic.com.
The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
